Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and Economic Impact of Expanded TPMT Testing to Prevent Thiopurine-Induced Myelosuppression in Australia: A Budget Impact Analysis.

Clinical and translational science - 1 Feb 2026

Ianni Bella D, Ali Mohammad Afshar, Yiu Chin Hang, Tan Edwin C K, Lu Christine Y

Abstract excerpt

Testing thiopurine methyltransferase (TPMT) enzyme activity or genotype prior to thiopurine prescribing is recommended to reduce the risk of moderate to severe-and potentially fatal-myelosuppression in poor or intermediate TPMT metabolizers. Despite this, only about one-third of individuals prescribed thiopurines in Australia currently receive TPMT testing. The budgetary implications of expanding testing to align...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Australia
Share to Azathioprine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone Marrow Diseases

Share to Cost-Benefit Analysis

Share to Hospitalization

Share to Mercaptopurine

Share to Methyltransferases

Share to Pharmacogenomic Testing

Source

Open in PubMed Open full text

Identifiers

PMID: 41614408
DOI: 10.1111/cts.70389
PMCID: PMC12856697

Genes

TPMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and Economic Impact of Expanded TPMT Testing to Prevent Thiopurine-Induced Myelosuppression in Australia: A Budget Impact Analysis.PMID 41614408Read ↗

The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine.Semantic proximity Read ↗

Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain.Semantic proximity Read ↗

Clinical Utility and Cost‐Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine‐Induced Myelosuppression: A Genotype‐First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease BioresourceSemantic proximity Read ↗

TPMT and NUDT15 testing for thiopurine therapy: A major tertiary hospital experience and lessons learnedSemantic proximity Read ↗

Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.Semantic proximity Read ↗

Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis.Semantic proximity Read ↗

Thiopurine S-methyltransferase testing for averting drug toxicity: a meta-analysis of diagnostic test accuracy.Semantic proximity Read ↗

Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review.Semantic proximity Read ↗

A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia.Semantic proximity Read ↗

Thiopurine S-methyltransferase testing for averting drug toxicity in patients receiving thiopurines: a systematic review.Semantic proximity Read ↗

Utility of assessing thiopurine S-methyltransferase polymorphisms before azathioprine therapy.Semantic proximity Read ↗

Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.